CardiovascularINJECTIONGeneric
AMPHOTEC
AMPHOTERICIN B
Standard Dose
100MG/VIAL
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary
Approval overview AMPHOTEC is listed in Drugs@FDA under application 050729 (NDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient AMPHOTERICIN B Form and strength INJECTABLE, LIPID COMPLEX;INJECTION - 100MG/VIAL Sponsor ALKOPHARMA USA Submission history Latest submission status date: 1997-08-27 00:00:00.
Structured Monograph
Clinical summary
Approval overview AMPHOTEC is listed in Drugs@FDA under application 050729 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient AMPHOTERICIN B Form and strength INJECTABLE, LIPID COMPLEX;INJECTION - 100MG/VIAL Sponsor ALKOPHARMA USA Submission history Latest submission status date: 1997-08-27 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.